Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs NextEra Energy, Inc. (NEE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs NextEra Energy, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $298.84 (market cap $39.89B), while NextEra Energy, Inc. trades at $88.28 (market cap $183.45B). The key difference: NextEra Energy, Inc. is far larger — about 4.6× Alnylam Pharmaceuticals, Inc.'s market cap, and NextEra Energy, Inc. pays a 2.83% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | NEE | |
|---|---|---|
Market Cap | $39.89B | $183.45B |
Sector | Health | Utilities |
52-Week High | $491.22 | $97.88 |
52-Week Low | $278.09 | $69.77 |
Enterprise Value | $38.15B | $285.85B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
NextEra Energy (NEE) trades at $87.96, up 0.99% on the day, with a bearish technical signal despite positive earnings momentum. The company reported strong Q1 2026 EPS of $1.09, beating expectations, and maintains robust profitability with a 29.37% net income margin. Recent news highlights the Dominion deal as a major catalyst, while analyst consensus remains strongly bullish with a $104.43 price target representing 19% upside potential.
NEE presents a compelling long-term investment opportunity driven by clean energy demand and strategic partnerships, though near-term technical weakness and rising debt levels warrant caution. The stock's current valuation at 22.32x P/E appears reasonable given growth prospects, but regulatory uncertainty from recent acquisitions and capital-intensive operations pose execution risks for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →
